Condition
EGFR G719X
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (2)
Trial Status
Unknown1
Recruiting1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06517953Phase 2Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT05998993Not ApplicableNot Yet Recruiting
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
NCT05548348Phase 2Unknown
First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation
Showing all 3 trials